The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-05 and is reviewed periodically as new material appears.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
=== See also === Gary Lewis & the Playboys were a contemporary group founded and led by Gary Lewis, the son of Dean Martin's erstwhile comedy partner Jerry Lewis. With a sound likewise influenced by the British Invasion, their version of "This Diamond Ring" reached No. 1 in February 1965.
=== Ethanol === The first historical achievement in anesthesia occurred around 4000 BC in ancient Mesopotamia. This was the advent of ethanol (commonly known as drinking alcohol), the first general anaesthetic agent. These accounts of the anesthetic uses of ethanol come from the oldest known historical civilization of Sumer and are documented in the oldest known writing system cuneiform.
=== Early years: Frankfurt === Theodor W. Adorno was born as Theodor Ludwig Wiesengrund in Frankfurt on 11 September 1903, the only child of Maria Calvelli-Adorno della Piana (1865–1952) and Oscar Alexander Wiesengrund (1870–1946). His mother, a Catholic from Corsica, was once a professional singer, while his father, an assimilated Jew who had converted to Protestantism, ran a successful wine-export business. His mother wanted her son's surname to include her own, Adorno. Thus, his earliest publications carried the name Theodor Wiesengrund-Adorno. Upon his application for US citizenship, his father's surname, Wiesengrund, was dropped from the name. His mother and aunt provided a vibrant musical life during his childhood. Maria was a singer who could boast of having performed in Vienna at the Imperial Court, while her sister, Agathe, who lived with them, had made a name for herself as both a singer and pianist. He was not only a precocious child but, as he recalled later in life, a child prodigy who could play pieces by Beethoven on the piano by the time he was twelve. At the age of six, he attended the Deutschherren Middle School before transferring to the Kaiser-Wilhelm Gymnasium, where he studied from 1913 to 1921. Before his graduation at the top of his class, Adorno was already swept up by the revolutionary mood of the time, as is evidenced by his reading of György Lukács's The Theory of the Novel that year, as well as by his fascination with Ernst Bloch's The Spirit of Utopia, of which he would later write:
=== Reductive half === The action of GR proceeds through two distinct half reactions, a reductive half mechanism followed by an oxidative half. In the first half, NADPH reduces FAD present in GSR to produce a transient FADH− anion. This anion then quickly breaks a disulfide bond of Cys58 - Cys63, forming a short lived covalent bond a stable charge-transfer complex between the flavin and Cys63. The now oxidized NADP+ is released and is subsequently replaced by a new molecule of NADPH. This is the end of the so-called reductive half of the mechanism.
Sources: en.wikipedia.org
In 2022, Church's Texas Chicken operated more than 1,500 locations worldwide. Its international locations include Bahrain, Belarus, Cambodia, Canada, Costa Rica, Curaçao, Guyana, Honduras, Indonesia, Iraq, Jordan, Laos, Malaysia, Mexico, New Zealand, Oman, Pakistan, Puerto Rico, Saudi Arabia, Qatar, Singapore, St. Lucia, Thailand, Trinidad & Tobago, United Arab Emirates, Venezuela and Vietnam. However, Church's Texas Chicken's operation in Thailand, which is operated under license by PTT OR (PTT Oil and Retail Business Public Company Limited) as Texas Chicken was discontinued on 30 September 2024 as it was announced in their official Facebook page after 9 years of its operation. As of 30 September 2024, PTT OR operates 97 Texas Chicken locations nationwide in Thailand.
Maximum diversity often leads to maximum stress. In the end we survive, but only by the skin of our teeth. This is the confession of faith of a scientific heretic. Perhaps I may claim as evidence for progress in religion the fact that we no longer burn heretics.
The International Mass Spectrometry Foundation (IMSF) is a non-profit scientific organization in the field of mass spectrometry. It operates the International Mass Spectrometry Society, which consists of 37 member societies and sponsors the International Mass Spectrometry Conference that is held once every two years.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.